The mission is remission: health economic consequences of achieving full remission with antidepressant treatment for depression.
The aim of the present study was to determine the magnitude of the impact of treating depression to full remission on cost and health-related quality of life. In a naturalistic longitudinal survey recordings of resource use and quality of life were carried out among depressed patients treated with antidepressant therapy in 56 Swedish primary care clinics. We found that a total of 52% of the patients achieved full remission during the study period. Remitting patients had, on average, three outpatient visits less than non-remitting patients (p < 0.01), 22 fewer sick leave days (p = 0.01), which translated into a significantly lower total cost (Euro 2700) compared with non-remitting patients (p < 0.01). Health-related quality-of-life scores improved by 40% for remitting patients when compared with non-remitting ones (p < 0.01). We conclude that remission has a substantial health economic impact on patients treated for depression, which further strengthens the importance of aiming for full remission in the treatment of depression.
Sobocki
P
P
Department of Learning, Informatics, Management and Ethics, Medical Management Centre, Karolinska Institutet, Stockholm, Sweden. patrik.s@healtheconomics.se
Ekman
M
M
Agren
H
H
Runeson
B
B
Jönsson
B
B
D000328:Adult; D000553:Ambulatory Care / Q000191:economics / Q000706:statistics & numerical data; D000928:Antidepressive Agents / Q000191:economics / Q000627:therapeutic use*; D017281:Cost of Illness; D003362:Cost-Benefit Analysis; D003866:Depressive Disorder / Q000188:drug therapy* / Q000191:economics; D005260:Female; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D011788:Quality of Life; D012074:Remission Induction; D018582:Sick Leave / Q000191:economics / Q000706:statistics & numerical data; D013997:Time Factors; D016896:Treatment Outcome
D000928:Antidepressive Agents